Genetic panel testing identifies pathogenic mutations in only a minority of SCAD patients, highlighting the need for further research into its molecular mechanisms.
Only a minority of patients with SCAD who undergo genetic evaluation have a likely pathogenic mutation identified on gene panel testing. Even fewer exhibit clinical features of connective tissue disorder. These findings underscore the need for further studies to elucidate the molecular mechanisms of SCAD.
Henkin et al. (Wed,) studied this question.